EQ/T. Rowe Price Health Sciences Portfolio
Data updated: 2026-05-26
C000203168 — EQ/T. Rowe Price Health Sciences Portfolio data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $158.96M AUM · 1.20% expense ratio · 12.7% 1-yr return. From SEC regulatory filings.
C000203168 Fund Overview
EQ/T. Rowe Price Health Sciences Portfolio is a US mutual fund managed by Eq Advisors Trust, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Eq Advisors Trust
- Category: United States Health Care Equity
- Assets under management: $158.96M
- 1-year return: 12.7%
- SEC CIK: 0001027263
- SEC series ID: S000062644
- Share class ID: C000203168
C000203168 Holdings
Top 10 holdings of EQ/T. Rowe Price Health Sciences Portfolio by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Eli Lilly & Co. | 10.20% |
| Thermo Fisher Scientific, Inc. | 4.13% |
| Intuitive Surgical, Inc. | 3.71% |
| Stryker Corp. | 3.53% |
| Merck & Co., Inc. | 3.48% |
| AstraZeneca plc | 3.21% |
| UnitedHealth Group, Inc. | 3.11% |
| Argenx SE | 3.04% |
| AbbVie, Inc. | 2.91% |
| Regeneron Pharmaceuticals, Inc. | 2.71% |
C000203168 Portfolio Allocation
Asset-class allocation of EQ/T. Rowe Price Health Sciences Portfolio by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.5% |
| Cash & Equivalents | 1.0% |
C000203168 Performance
Total returns for C000203168 (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | -6.2% |
| 1 year | 12.7% |
| 3 years (annualised) | 6.5% |
| 5 years (annualised) | 2.6% |
C000203168 Risk Information
Risk metrics for C000203168, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 17.1%
C000203168 Costs and Fees
C000203168 costs about $120 per $10,000 invested per year in fund expenses.
- Net expense ratio: 1.20%
- Gross expense ratio: 1.37%
- Portfolio turnover: 42%
- Brokerage commissions: 2.87 bps of average net assets (SEC N-CEN)
C000203168 Cashflows
Over the 12 months to 2026-03, EQ/T. Rowe Price Health Sciences Portfolio had net outflows of $17.89M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-03 | −$1.25M |
| 2026-02 | −$2.31M |
| 2026-01 | −$3.03M |
| 2025-12 | −$2.05M |
| 2025-11 | −$1.87M |
| 2025-10 | −$614.76K |
C000203168 Debt Constituents
No individual debt constituents are reported in EQ/T. Rowe Price Health Sciences Portfolio's latest SEC N-PORT filing.
C000203168 Prospectus and SEC Filings
Official EQ/T. Rowe Price Health Sciences Portfolio filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.